The Mouse Monoclonal anti-APOA1 antibody has been validated for WB and ELISA. It is suitable to detect APOA1 in samples from Human. There are 2+ publications available.
APOA1
Reactivity: Human
WB, IHC, IF
Host: Rabbit
Polyclonal
unconjugated
Application Notes
ELISA: 1/10000
Restrictions
For Research Use only
Format
Liquid
Buffer
Ascitic fluid containing 0.03 % sodium azide.
Preservative
Sodium azide
Precaution of Use
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage
4 °C,-20 °C
Storage Comment
Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.
Brown, Rea, Hamon, Hixson, Boerwinkle, Clark, Sing: "The contribution of individual and pairwise combinations of SNPs in the APOA1 and APOC3 genes to interindividual HDL-C variability." in: Journal of molecular medicine (Berlin, Germany), Vol. 84, Issue 7, pp. 561-72, (2006) (PubMed).
Martina, Benso, Gigliardi, Masha, Origlia, Granata, Ghigo: "Short-term dehydroepiandrosterone treatment increases platelet cGMP production in elderly male subjects." in: Clinical endocrinology, Vol. 64, Issue 3, pp. 260-4, (2006) (PubMed).
Target
APOA1
(Apolipoprotein A-I (APOA1))
Alternative Name
APOA1
Background
APOA1: apolipoprotein A-I, it is the major protein component of high density lipoprotein (HDL) in plasma. The protein promotes cholesterol efflux from tissues to the liver for excretion, and it is a cofactor for lecithin cholesterolacyltransferase (LCAT) which is responsible for the formation of most plasma cholesteryl esters. Defects in the Apolipoprotein A I gene are associated with HDL deficiency and Tangier disease. The therapeutic potential of apoA-I has been recently assessed in patients with acute coronary syndromes, using a recombinant form of a naturally occurring variant of apoA-I. The availability of recombinant normal apoA-I should facilitate further investigation into the potential usefulness of apoA-I in preventing atherosclerotic vascular diseases.